Choose Your Country or Region

Anti-SAE1 Rabbit Antibody [B2F24]

Catalog No.: F3862

Application: Reactivity: Human

Usage Information

Dilution
WB1:10000 - 1:50000 IP1:50 - 1:70 IF1:500 FCM1:230

Application
WB, IP, IF, FCM

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
38 kDa

Datasheet & SDS

Biological Description

Specificity
Anti-SAE1 Rabbit Antibody [B2F24] detects endogenous levels of total SAE1 protein.

Clone
B2F24

Synonym(s)
AOS1, SUA1, UBLE1A, SAE1, SUMO-activating enzyme subunit 1, Ubiquitin-like 1-activating enzyme E1A

Background
SUMOylation, a post-translational modification involving the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to target substrates, plays a critical role in diverse cellular processes such as transcriptional regulation, protein stability, cell cycle control, and apoptosis. SAE1 (SUMO-activating enzyme subunit 1), a core component of the heterodimeric SUMO-activating enzyme complex, is indispensable for initiating SUMOylation. Elevated expression of SAE1 has been linked to the onset and progression of multiple cancers, including glioma, gastric cancer, and Myc-driven tumors. High SAE1 levels are frequently detected in a range of malignancies and show strong correlations with tumor initiation and progression. In hepatocellular carcinoma, SAE1 overexpression is associated with tumor metastasis, advanced disease stage, and unfavorable prognosis. Similarly, in colon cancer, SAE1 is markedly upregulated, and its inhibition triggers cell cycle arrest, apoptosis, and suppressed cellular proliferation. In glioma, increased SAE1 expression enhances cell proliferation and migration by promoting both SUMOylation and phosphorylation of protein kinase B (PKB/AKT), thereby driving glioma development in vitro and in vivo.

Background

SUMOylation, a post-translational modification involving the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to target substrates, plays a critical role in diverse cellular processes such as transcriptional regulation, protein stability, cell cycle control, and apoptosis. SAE1 (SUMO-activating enzyme subunit 1), a core component of the heterodimeric SUMO-activating enzyme complex, is indispensable for initiating SUMOylation. Elevated expression of SAE1 has been linked to the onset and progression of multiple cancers, including glioma, gastric cancer, and Myc-driven tumors. High SAE1 levels are frequently detected in a range of malignancies and show strong correlations with tumor initiation and progression. In hepatocellular carcinoma, SAE1 overexpression is associated with tumor metastasis, advanced disease stage, and unfavorable prognosis. Similarly, in colon cancer, SAE1 is markedly upregulated, and its inhibition triggers cell cycle arrest, apoptosis, and suppressed cellular proliferation. In glioma, increased SAE1 expression enhances cell proliferation and migration by promoting both SUMOylation and phosphorylation of protein kinase B (PKB/AKT), thereby driving glioma development in vitro and in vivo.

References
https://pubmed.ncbi.nlm.nih.gov/39742381/ https://pubmed.ncbi.nlm.nih.gov/33477333/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%